List of Actimis Pharmaceuticals patents | 7 results

Name	Description	Current Assignee	Patent Jurisdiction	Patent Number	Date of Patent
‌ US Patent 7812160 Pyrimidine derivatives useful for the treatment of diseases mediated by CRTH2	Patent 7812160 was granted and assigned to Actimis Pharmaceuticals on October, 2010 by the United States Patent and Trademark Office.	Actimis Pharmaceuticals	United States Patent and Trademark Office	7812160	October 12, 2010
‌ US Patent 7960393 Pyrimidine derivatives useful for the treatment of diseases mediated by CRTH2	Patent 7960393 was granted and assigned to Actimis Pharmaceuticals on June, 2011 by the United States Patent and Trademark Office.	Actimis Pharmaceuticals	United States Patent and Trademark Office	7960393	June 14, 2011
‌ US Patent 7750014 Imidazo[1,2-C]pyrimidinylacetic acid derivatives	Patent 7750014 was granted and assigned to Actimis Pharmaceuticals on July, 2010 by the United States Patent and Trademark Office.	Actimis Pharmaceuticals	United States Patent and Trademark Office	7750014	July 6, 2010
‌ US Patent 8324229 Alkylthio pyrimidines as CRTH2 antagonists	Patent 8324229 was granted and assigned to Actimis Pharmaceuticals on December, 2012 by the United States Patent and Trademark Office.	Actimis Pharmaceuticals	United States Patent and Trademark Office	8324229	December 4, 2012
‌ US Patent 8314116 2-S-benzyl substituted pyrimidines as CRTH2 antagonists	Patent 8314116 was granted and assigned to Actimis Pharmaceuticals on November, 2012 by the United States Patent and Trademark Office.	Actimis Pharmaceuticals	United States Patent and Trademark Office	8314116	November 20, 2012
‌ US Patent 8507005 Particulates of a CRTH2 antagonist	Patent 8507005 was granted and assigned to Actimis Pharmaceuticals on August, 2013 by the United States Patent and Trademark Office.	Actimis Pharmaceuticals	United States Patent and Trademark Office	8507005	August 13, 2013
‌ US Patent 8541419 Isotopically enriched pyrimidin-5-yl acetic acid derivatives as CRTH2 antagonists	Patent 8541419 was granted and assigned to Actimis Pharmaceuticals on September, 2013 by the United States Patent and Trademark Office.	Actimis Pharmaceuticals	United States Patent and Trademark Office	8541419	September 24, 2013